Discloses a recombinant follicle stimulating hormone (FSH) including alpha 2,3- and alpha 2,6-sialylation content wherein 10% or more of the total sialylation is a 2,3- sialylation and a sialic acid content of 5 mol/mol or greater. Discloses a FSH including alpha 2,6- sialylation in an amount 15- 30 % of the total sialylation. Discloses a recombinant FSH with disclosed sialylation content which, in addition to the alpha 2,3- and alpha 2,6-sialylation, further includes alpha 2,8-sialylation. The FSH may be produced or expressed in a human cell line. Discloses a recombinant FSH with disclosed sialylation content which may be formulated as a pharmaceutical preparation for use in the manufacture of a medicament for treatment of infertility.
